3-甲氨基-3'-(2-甲基苯基)-丙醇 | 69888-75-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 3-甲氨基-3'-(2-甲基苯基)-丙醇
• 英文名称: 3-N-methyl-3-phenyl-propanol
• 英文别名: 3-Methylamino-3-phenylpropanol；3-methylamino-3-phenyl-propan-1-ol；3-(Methylamino)-3-phenylpropan-1-ol
• CAS: 69888-75-1
• 化学式: C₁₀H₁₅NO
• mdl: MFCD03412704
• 分子量: 165.235
• InChiKey: FDYZMHZQSAYZNO-UHFFFAOYSA-N

物化性质

• 熔点：
  59-60 °C(Solv: ligroine (8032-32-4))
• 沸点：
  176-185 °C(Press: 16 Torr)
• 密度：
  1.103 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-甲氨基-3'-(2-甲基苯基)-丙醇 在 六甲基磷酰三胺 、 sodium hydroxide 、 仲丁基锂 作用下， 以 二氯甲烷 为溶剂， 反应 4.33h， 生成
  参考文献：
  名称：

  Origins of diastereoselectivity in the alkylation of N-substituted lactams and amides derived from optically active aminoalcohols

  摘要：

  The origins of diastereoselectivity in the alkylation of lactams la and Ib and amides 6a and 6b are discussed. A rigid intermediate in which the pyramidalized amide nitrogen chelated the alkoxide lithium cation is invoked. Further experiments conducted with different substrates' are in agreement with the proposed model, Furthermore this model can explain the differences observed previously between ephedrine and pseudoephedrine amide alkylation. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/0957-4166(96)00374-6
• 作为产物：
  描述：

  3-氨基-3-苯基-1-丙醇 在 lithium aluminium tetrahydride 作用下， 生成 3-甲氨基-3'-(2-甲基苯基)-丙醇
  参考文献：
  名称：

  Origins of diastereoselectivity in the alkylation of N-substituted lactams and amides derived from optically active aminoalcohols

  摘要：

  The origins of diastereoselectivity in the alkylation of lactams la and Ib and amides 6a and 6b are discussed. A rigid intermediate in which the pyramidalized amide nitrogen chelated the alkoxide lithium cation is invoked. Further experiments conducted with different substrates' are in agreement with the proposed model, Furthermore this model can explain the differences observed previously between ephedrine and pseudoephedrine amide alkylation. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/0957-4166(96)00374-6

文献信息

• PYRIMIDINE COMPOUND
  申请人：Matsushima Yuji

  公开号：US20110053912A1

  公开（公告）日：2011-03-03

  A novel and excellent method for preventing and/or treating diseases related to a cannabinoid type 2 receptor, based on an agonistic action on a cannabinoid type 2 receptor. It was found that a hetero ring derivative mainly having two substituents, for example, a pyrimidine-5-carboxamide derivative having a substituent amino group at the 2-position, exhibits a potent agonistic action on a cannabinoid type 2 receptor, and can be an agent for preventing and/or treating diseases related to a cannabinoid type 2 receptor such as inflammatory diseases, pain, and the like.

  一种预防和/或治疗与大麻素2型受体相关疾病的新颖优秀方法，基于对大麻素2型受体的激动作用。发现一种异核环衍生物主要具有两个取代基，例如，在2-位置具有取代基氨基的嘧啶-5-羧酰胺衍生物，表现出对大麻素2型受体的强效激动作用，可以成为预防和/或治疗与大麻素2型受体相关疾病，如炎症性疾病、疼痛等的药物。
• [EN] INHIBITOR OF MONOAMINE UPTAKE<br/>[FR] INHIBITEUR DE LA CAPTURE DE LA MONOAMINE
  申请人：LILLY CO ELI

  公开号：WO2002070457A1

  公开（公告）日：2002-09-12

  The present invention provides compounds and methods for the inhibition of monoamine uptake in mammals.

  本发明提供了一种用于抑制哺乳动物中单胺摄取的化合物和方法。
• Novel phosphorus-containing prodrugs
  申请人：Erion D. Mark

  公开号：US20070249564A1

  公开（公告）日：2007-10-25

  Novel cyclic phosphoramidate prodrugs of drugs of formula I their use in delivery of drugs to the liver, their use in enhancing oral bioavailability, and their method of preparation are described.

  本文介绍了式I药物的新型环状磷酰胺酰化预药，其在药物传递到肝脏方面的应用、增强口服生物利用度方面的应用以及其制备方法。
• ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE
  申请人：McComas Casey Cameron

  公开号：US20100029641A1

  公开（公告）日：2010-02-04

  The present invention is directed to aryl sulfamide derivatives of formula I: or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, vasomotor symptoms, sexual dysfunction, gastrointestinal disorders and genitourinary disorder, depression disorders, endogenous behavioral disorders, cognitive disorders, diabetic neuropathy, pain, and other diseases or disorders.

  本发明涉及公式I的芳基磺酰胺衍生物： 或其药学上可接受的盐、立体异构体或互变异构体，它们是单胺再摄取抑制剂，包含这些衍生物的组合物以及它们的使用方法，用于预防和治疗多种疾病或疾病，包括但不限于血管运动症状、性功能障碍、胃肠障碍和泌尿生殖障碍、抑郁症、内源性行为障碍、认知障碍、糖尿病神经病变、疼痛和其他疾病或障碍。
• Novel Phosphorus-Containing Prodrugs
  申请人：Erion Mark D.

  公开号：US20080125605A1

  公开（公告）日：2008-05-29

  Novel cyclic phosphoramidate prodrugs of drugs of formula I their use in delivery of drugs to the liver, their use in enhancing oral bioavailability, and their method of preparation are described.

  本发明涉及一种新型环磷酰胺酰胺酯前药，其为公式I药物的前药，其在药物传递到肝脏方面的应用，其在增强口服生物利用度方面的应用，以及其制备方法。